Clinical Trial Update: Efficacy and Tolerability of MLC601 in Patients With Mild to Moderate Alzheimer Disease Who Were Unable to Tolerate or Failed to Benefit From Treatment With Rivastigmine [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the efficacy and tolerability of MLC601 in patients with mild to moderate Alzheimer's disease who were unable to tolerate or had not …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• MLC601

Snippet

Sponsor: Shahid Beheshti University of Medical Sciences | Conditions: Alzheimer Disease | Phase 2 | Status: COMPLETED